- Home
- IBRX vs TTAM Comparison
IBRX vs TTAM Comparison
Compare IBRX & TTAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- TTAM
- Stock Information
- Founded
- IBRX 2014
- TTAM 1902
- Country
- IBRX United States
- TTAM Belgium
- Employees
- IBRX N/A
- TTAM N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- TTAM
- Sector
- IBRX Health Care
- TTAM
- Exchange
- IBRX Nasdaq
- TTAM NYSE
- Market Cap
- IBRX 2.4B
- TTAM 2.6B
- IPO Year
- IBRX N/A
- TTAM 2025
- Fundamental
- Price
- IBRX $2.87
- TTAM $12.81
- Analyst Decision
- IBRX Strong Buy
- TTAM Strong Buy
- Analyst Count
- IBRX 5
- TTAM 5
- Target Price
- IBRX $11.40
- TTAM $17.00
- AVG Volume (30 Days)
- IBRX 10.1M
- TTAM 195.3K
- Earning Date
- IBRX 08-11-2025
- TTAM 05-05-2025
- Dividend Yield
- IBRX N/A
- TTAM 0.63%
- EPS Growth
- IBRX N/A
- TTAM 169.03
- EPS
- IBRX N/A
- TTAM 0.96
- Revenue
- IBRX $31,222,000.00
- TTAM $1,626,740,000.00
- Revenue This Year
- IBRX $567.98
- TTAM $5.60
- Revenue Next Year
- IBRX $160.56
- TTAM $8.46
- P/E Ratio
- IBRX N/A
- TTAM $13.28
- Revenue Growth
- IBRX 10238.41
- TTAM 19.25
- 52 Week Low
- IBRX $1.83
- TTAM $10.80
- 52 Week High
- IBRX $7.63
- TTAM $17.78
- Technical
- Relative Strength Index (RSI)
- IBRX 49.40
- TTAM N/A
- Support Level
- IBRX $2.77
- TTAM N/A
- Resistance Level
- IBRX $3.24
- TTAM N/A
- Average True Range (ATR)
- IBRX 0.23
- TTAM 0.00
- MACD
- IBRX -0.03
- TTAM 0.00
- Stochastic Oscillator
- IBRX 19.74
- TTAM 0.00
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About TTAM TITAN AMERICA SA
Titan America SA is a vertically integrated, multi-regional manufacturer and supplier of heavy building materials and services operating on the Eastern Seaboard. The Company, through its wholly owned subsidiaries, operates in the manufacture, distribution, and sale of cement, fly ash, aggregates, ready-mix concrete, and concrete blocks to resellers and construction contractors in the Eastern region of the United States.